Teligent Inc

Teligent — 35th Annual J.P. Morgan Healthcare Conference (January 2017)

20 slides from Teligent's conference presentation, Jan 11, 2017

  1. Slide 1: Teligent, Inc. 35th Annual J.P. Morgan Healthcare Conference

    Slide 1: Teligent, Inc. 35th Annual J.P. Morgan Healthcare Conference

    Teligent, Inc. 35 th Annual J.P. Morgan Healthcare Conference January 11, 2017 Jason Grenfell - Gardner | CEO Jenniffer Collins | CFO NASDAQ Global Select: TLGT

  2. Slide 2: Safe Harbor Statement

    Slide 2: Safe Harbor Statement

    Safe Harbor Statement 2 Except for historical facts, the statements in this presentation, as well as oral statements or other written statements made or to be made by Teligent , Inc . , are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and in

  3. Slide 3: Investment Highlights

    Slide 3: Investment Highlights

    Investment Highlights Specialty Generics Targeting Attractive Markets • Fully - integrated specialty generics pharmaceutical company • Pursuing Topical , Injectable, Complex and Ophthalmic markets Growing Development Pipeline • 36 ANDAs on file in US with $2.0 bn Total Addressable Market 1 , we rece

  4. Slide 4: Our Executive Management Team

    Slide 4: Our Executive Management Team

    4 Our Executive Management Team is dedicated to driving the company’s long - term transformation into a science - centered specialty generics pharmaceutical company. Executive Team Jason Grenfell - Gardner, President & Chief Executive Officer Jason joined Teligent in 2012 and brought significant exp

  5. Slide 5: Building Our R&D Track Record

    Slide 5: Building Our R&D Track Record

    Building Our R&D Track Record 5 Annual US ANDA Submissions and Approvals 8 13 19 31 36 11 2014 2015 1 2013 2016 2 2012 Pending Filed ANDAs Cumulative Approvals Produc t Count 1 4 6 11 20 Net Sales (MM) $8.6 $18.2 $33.7 $44.5 $65 - 72 1 R&D Spend (MM) $2.8 $2.8 $6.9 $13.2 28 - 32% 1 Headcount 42 54 8

  6. Slide 6: We Continue to Diversify Our Portfolio

    Slide 6: We Continue to Diversify Our Portfolio

    We Continue to Diversify Our Portfolio Our expansion is underway to deliver a diversified portfolio through TICO : • T opical: Cornerstone of our expertise • I njectable: Favorable market opportunities • C omplex: Unique product/regulatory situations • O phthalmic: Leverage our infrastructure We hav

  7. Slide 7: Our Transformation Is Driven By Diversification and Growth

    Slide 7: Our Transformation Is Driven By Diversification and Growth

    Our Transformation Is Driven By Diversification and Growth 7 # of Products in North American Portfolio Regulatory Applications On File Diversification of Commercial Portfolio Transition To Prescription Products 0 5 10 15 20 25 30 35 3Q 2010 3Q 2016 US Canada 0% 20% 40% 60% 80% 100% 3Q 2010 3Q 2016 T

  8. Slide 8: TICO: Topical Market

    Slide 8: TICO: Topical Market

    1 • The addressable US topical market is $13.1bn, of which generics make up $5.3bn; the generic space has grown rapidly, with a 3 - year CAGR of 59%, while volumes have increased 9% • The market has 6 major players who control about 65% of the script volume, with significant barriers to entry • Cons

  9. Slide 9: Topical: Cornerstone of Expertise

    Slide 9: Topical: Cornerstone of Expertise

    Topical: Cornerstone of Expertise Attractive Market • $5.5bn US generic market, growing faster than 59% over three years, driven by price • Historical strength and expertise for Teligent Broad Scope of Organic R&D Opportunities • Teligent to file approximately 14 more ANDAs for all commercially reas

  10. Slide 10: Expansion Underway to Increase R&D and Production Capacity and Capabilities

    Slide 10: Expansion Underway to Increase R&D and Production Capacity and Capabilities

    Expansion Underway to Increase R&D and Production Capacity and Capabilities Site Overview • 33,500 sq ft campus, including an FDA - approved facility to make pharmaceuticals and medical devices • Capability to develop and produce creams, ointments, lotions, gels, solutions and suspensions • Most rec

  11. Slide 11: Where We Are Going

    Slide 11: Where We Are Going

    11 Where We Are Going Teligent is investing in high - tech and high - speed equipment to strengthen our capabilities.

  12. Slide 12: Phasing of Renovation and Construction

    Slide 12: Phasing of Renovation and Construction

    Phasing of Renovation and Construction 12 Phase 1: complete R&D Lab and administrative office renovations Phase 2: underway Break ground on topical Manufacturing facility renovation and expansion Phase 3: 1 - 2Q17 Build out of sterile injectable manufacturing suite Phase 4: 2 - 3Q17 Transition to Ne

  13. Slide 13: TICO: Injectable Market

    Slide 13: TICO: Injectable Market

    Sales Brand 25% Branded Generic 26% Generic 49% TICO: Injectable Market 13 Source: IMS Health, MAT November 2016; Wall Street research • The market for generic injectables offers attractive opportunities High barriers to entry given required sterile manufacturing and increased regulatory scrutiny by

  14. Slide 14: Evolving Beyond Topicals

    Slide 14: Evolving Beyond Topicals

    Evolving Beyond Topicals Expand In - House Development • Establish a robust cycle of in - house lab - to - CMO transfers • Expand development and analytical team for in - house formulation Access CMO Network • Access manufacturing capacity beyond topicals • Partner with high quality CMOs that suppor

  15. Slide 15: Pipeline Is Well-Positioned for New GDUFA Landscape

    Slide 15: Pipeline Is Well-Positioned for New GDUFA Landscape

    Pipeline Is Well - Positioned for New GDUFA Landscape 15 15 ANDAs were filed in 2015, 12 ANDAs were filed in 2016 Sources: IMS Health, MAT November 2016; Company data Does not include submissions filed with partners. # of ANDA Filings % of Total Addressable Market of ANDAs on File 28 8 0 5 10 15 20

  16. Slide 16: Growing, Increasingly Diverse Pipeline

    Slide 16: Growing, Increasingly Diverse Pipeline

    Growing, Increasingly Diverse Pipeline Delivery/Therapy Area Focus Commercial/Regulatory Status Teligent Label Product and Pipeline Mix: Total of 102 products US & 39 Canada Source: Company data 16 16 36 22 4 19 1 2 1 27 5 7 0 5 10 15 20 25 30 35 40 45 50 Currently marketed products Previously Appro

  17. Slide 17: Financial Highlights – 2016 Guidance

    Slide 17: Financial Highlights – 2016 Guidance

    Financial Highlights – 2016 Guidance `` - 1 2 3 4 5 6 7 8 2014 2015 2016 Guidance $ m Adjusted EBITDA Submitted 12 ANDAs with the FDA, and 8 Applications in Canada in 2016. We expect to spend between 28% and 32% of total revenue on R&D by the end of 2016. We expect operating income between $1.0 and

  18. Slide 18: Investment Highlights

    Slide 18: Investment Highlights

    Investment Highlights Specialty Generics Targeting Attractive Markets • Fully - integrated specialty generics pharmaceutical company • Pursuing Topical , Injectable, Complex and Ophthalmic markets Growing Development Pipeline • 36 ANDAs on file in US with $2.0 bn Total Addressable Market 1 , we rece

  19. Slide 19: Teligent

    Slide 19: Teligent

    Teligent

  20. Slide 20

    Slide 20

Source: SEC EDGAR · 8-K filed Jan 11, 2017

More decks from Teligent Inc